_MEMBER_CNet-SVM,_MEMBER_Enet-SVM,_MEMBER_L2SCAD-SVM,_MEMBER_SCAD-SVM,_MEMBER_SGLasso-SVM,_MEMBER_SVM-RFE,_MEMBER_mRMR-SVM,_LogP_CNet-SVM,_LogP_Enet-SVM,_LogP_L2SCAD-SVM,_LogP_SCAD-SVM,_LogP_SGLasso-SVM,_LogP_SVM-RFE,_LogP_mRMR-SVM,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,1,1,1,0,-6.1,-3.3,-4,-3.8,-2.3,-3.1,0,M5885,NABA MATRISOME ASSOCIATED,M1111110,6,0
1,0,1,1,0,1,1,-3.3,0,-2.1,-2.8,0,-3.4,-2.5,R-HSA-388396,GPCR downstream signalling,M1011011,5,0
1,0,1,1,0,1,1,-7.4,0,-2.4,-3.1,0,-2.8,-7.7,GO:0070848,response to growth factor,M1011011,5,0
1,0,1,1,0,1,1,-5.1,0,-3,-2.6,0,-3.2,-2.3,R-HSA-372790,Signaling by GPCR,M1011011,5,0
1,0,0,1,0,1,1,-4,0,0,-4,0,-2.8,-7,hsa04014,Ras signaling pathway,M1001011,4,0
1,0,0,1,0,1,1,-3.1,0,0,-2.6,0,-3.2,-2.3,GO:0045596,negative regulation of cell differentiation,M1001011,4,0
1,0,0,1,0,1,1,-5.3,0,0,-2.7,0,-3.3,-4.4,GO:0035239,tube morphogenesis,M1001011,4,0
1,0,1,0,0,1,1,-2.7,0,-2.4,0,0,-3.9,-3.9,GO:0001501,skeletal system development,M1010011,4,0
1,0,0,1,0,1,1,-8.5,0,0,-4.4,0,-2.7,-10,hsa05200,Pathways in cancer,M1001011,4,0
1,0,0,1,0,1,1,-4.4,0,0,-4.4,0,-3.1,-4.5,GO:0030323,respiratory tube development,M1001011,4,0
1,0,0,1,0,1,1,-2.4,0,0,-3.7,0,-2.5,-2.5,GO:0009416,response to light stimulus,M1001011,4,0
1,0,0,1,0,1,1,-4.3,0,0,-4.2,0,-3,-4.4,GO:0060541,respiratory system development,M1001011,4,0
1,0,0,1,0,1,1,-5.2,0,0,-3.9,0,-2.7,-2.7,WP382,MAPK signaling pathway,M1001011,4,0
1,0,0,1,0,1,1,-11,0,0,-4.5,0,-3.3,-12,WP4262,Breast cancer pathway,M1001011,4,0
1,0,0,1,0,1,1,-4.1,0,0,-3.2,0,-2,-11,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M1001011,4,0
0,0,1,0,1,1,1,0,0,-3.1,0,-2.7,-6.6,-2.6,M5884,NABA CORE MATRISOME,M0010111,4,0
1,0,0,1,0,1,1,-12,0,0,-4.6,0,-3.4,-12,hsa05224,Breast cancer,M1001011,4,0
1,0,0,1,0,1,1,-3,0,0,-4.7,0,-3.1,-2,GO:0009314,response to radiation,M1001011,4,0
1,0,0,1,0,1,1,-4.9,0,0,-3.7,0,-2.5,-5,hsa04010,MAPK signaling pathway,M1001011,4,0
1,0,0,1,0,1,1,-4.5,0,0,-4.4,0,-3.2,-4.6,GO:0030324,lung development,M1001011,4,0
1,0,0,0,0,1,1,-4.1,0,0,0,0,-3.1,-4.3,GO:0048514,blood vessel morphogenesis,M1000011,3,0
1,0,0,0,0,1,1,-2.9,0,0,0,0,-3,-7.4,WP306,Focal adhesion,M1000011,3,0
1,0,0,1,0,1,0,-3.5,0,0,-2.9,0,-3.6,0,GO:0007610,behavior,M1001010,3,0
1,0,0,0,0,1,1,-3.1,0,0,0,0,-3.2,-4.6,GO:0048762,mesenchymal cell differentiation,M1000011,3,0
1,0,0,0,0,1,1,-3.1,0,0,0,0,-3.1,-3.1,GO:0060173,limb development,M1000011,3,0
1,0,0,0,0,1,1,-3.3,0,0,0,0,-3.4,-7.4,WP4172,PI3K-Akt signaling pathway,M1000011,3,0
1,0,0,0,0,1,1,-4.9,0,0,0,0,-2.8,-3.9,GO:0001568,blood vessel development,M1000011,3,0
0,0,1,0,0,1,1,0,0,-4.6,0,0,-5.2,-2.6,GO:0030198,extracellular matrix organization,M0010011,3,0
1,0,0,0,0,1,1,-6.8,0,0,0,0,-3.2,-4.4,GO:0048732,gland development,M1000011,3,0
1,0,0,0,0,1,1,-3.3,0,0,0,0,-3.4,-7.3,hsa04151,PI3K-Akt signaling pathway,M1000011,3,0
1,0,1,0,0,1,0,-7.2,0,-2.8,0,0,-2.3,0,M5883,NABA SECRETED FACTORS,M1010010,3,0
1,0,0,1,0,0,1,-4.1,0,0,-4.1,0,0,-2.9,GO:0042063,gliogenesis,M1001001,3,0
0,0,1,0,0,1,1,0,0,-3.3,0,0,-2.6,-2.6,GO:2000147,positive regulation of cell motility,M0010011,3,0
1,0,1,0,0,0,1,-6.3,0,-2.5,0,0,0,-7.9,GO:0071363,cellular response to growth factor stimulus,M1010001,3,0
0,0,1,0,0,1,1,0,0,-3.2,0,0,-2.6,-2.6,GO:0040017,positive regulation of locomotion,M0010011,3,0
1,0,0,0,0,1,1,-3.1,0,0,0,0,-3.1,-3.1,GO:0048736,appendage development,M1000011,3,0
1,0,0,0,0,1,1,-4.8,0,0,0,0,-2.8,-3.8,GO:0001944,vasculature development,M1000011,3,0
1,0,0,0,0,1,1,-3.5,0,0,0,0,-2.6,-2.6,GO:0030855,epithelial cell differentiation,M1000011,3,0
1,0,0,1,0,0,1,-2.2,0,0,-2.6,0,0,-2.3,R-HSA-1280215,Cytokine Signaling in Immune system,M1001001,3,0
1,0,1,0,0,0,1,-3.2,0,-2.7,0,0,0,-2.2,GO:0040007,growth,M1010001,3,0
0,0,1,0,0,1,1,0,0,-4.5,0,0,-5.2,-2.6,GO:0045229,external encapsulating structure organization,M0010011,3,0
1,0,0,0,0,1,1,-2.7,0,0,0,0,-3.9,-2.8,GO:0071407,cellular response to organic cyclic compound,M1000011,3,0
0,0,1,0,0,1,1,0,0,-4.6,0,0,-5.2,-2.6,GO:0043062,extracellular structure organization,M0010011,3,0
1,0,0,1,0,0,1,-4.4,0,0,-5.7,0,0,-6.3,WP4155,Endometrial cancer,M1001001,3,0
1,0,1,0,0,1,0,-2.9,0,-3.5,0,0,-3,0,R-HSA-375276,Peptide ligand-binding receptors,M1010010,3,0
1,0,0,0,0,1,1,-3.5,0,0,0,0,-3.6,-7.7,WP3932,Focal adhesion: PI3K-Akt-mTOR-signaling pathway,M1000011,3,0
0,0,1,0,0,1,1,0,0,-4.4,0,0,-5,-2.5,R-HSA-1474244,Extracellular matrix organization,M0010011,3,0
1,0,0,0,1,0,1,-2.1,0,0,0,-2.3,0,-4.1,GO:0001934,positive regulation of protein phosphorylation,M1000101,3,0
1,0,1,0,0,0,1,-2.4,0,-3,0,0,0,-3.6,GO:0070372,regulation of ERK1 and ERK2 cascade,M1010001,3,0
1,0,0,0,0,1,1,-4.1,0,0,0,0,-4.2,-4.2,GO:0001837,epithelial to mesenchymal transition,M1000011,3,0
0,0,1,0,0,1,1,0,0,-3.2,0,0,-2.6,-2.6,GO:0051272,positive regulation of cellular component movement,M0010011,3,0
1,0,0,1,0,1,0,-5.8,0,0,-2.9,0,-2.7,0,GO:0048729,tissue morphogenesis,M1001010,3,0
1,0,0,0,0,1,1,-4.6,0,0,0,0,-3.5,-6.1,hsa05165,Human papillomavirus infection,M1000011,3,0
1,0,0,0,0,1,1,-2.9,0,0,0,0,-3,-7.4,hsa04510,Focal adhesion,M1000011,3,0
1,0,1,0,0,1,0,-3.9,0,-3.3,0,0,-4,0,hsa04020,Calcium signaling pathway,M1010010,3,0
1,0,0,1,0,1,0,-4,0,0,-3.2,0,-2,0,GO:0002009,morphogenesis of an epithelium,M1001010,3,0
1,0,0,1,0,0,1,-4.2,0,0,-4.2,0,0,-3,hsa05205,Proteoglycans in cancer,M1001001,3,0
0,0,1,0,0,1,1,0,0,-3.3,0,0,-2.7,-2.7,GO:0030335,positive regulation of cell migration,M0010011,3,0
1,0,0,0,0,1,1,-2.7,0,0,0,0,-2.8,-4.1,GO:0060485,mesenchyme development,M1000011,3,0
1,0,1,0,0,0,1,-2.8,0,-3.4,0,0,0,-2.9,GO:0070374,positive regulation of ERK1 and ERK2 cascade,M1010001,3,0
1,0,1,0,0,0,1,-3.2,0,-2.7,0,0,0,-2.2,GO:0048589,developmental growth,M1010001,3,0
1,0,1,0,0,1,0,-2.3,0,-4.2,0,0,-2.4,0,R-HSA-373076,Class A/1 (Rhodopsin-like receptors),M1010010,3,0
1,0,0,0,0,1,1,-5.9,0,0,0,0,-3,-2.1,GO:0060322,head development,M1000011,3,0
0,0,1,0,0,1,1,0,0,-3.1,0,0,-2.6,-3.8,GO:0001503,ossification,M0010011,3,0
1,0,0,1,0,1,0,-3.8,0,0,-3,0,-3.9,0,GO:0071396,cellular response to lipid,M1001010,3,0
1,0,0,0,0,1,1,-7.5,0,0,0,0,-2.9,-2.9,GO:0061061,muscle structure development,M1000011,3,0
1,0,0,1,0,0,1,-3.7,0,0,-3,0,0,-7.5,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M1001001,3,0
1,0,0,0,0,0,1,-2.5,0,0,0,0,0,-2.6,GO:0060249,anatomical structure homeostasis,M1000001,2,0
1,0,0,0,0,0,1,-3.8,0,0,0,0,0,-3.9,GO:0008283,cell population proliferation,M1000001,2,0
0,0,1,0,0,0,1,0,0,-2.2,0,0,0,-3.6,GO:0051347,positive regulation of transferase activity,M0010001,2,0
1,0,0,0,0,0,1,-2.7,0,0,0,0,0,-2.8,GO:0001894,tissue homeostasis,M1000001,2,0
1,0,0,0,0,0,1,-3.8,0,0,0,0,0,-3.9,hsa01522,Endocrine resistance,M1000001,2,0
1,0,0,0,0,1,0,-6.1,0,0,0,0,-3.1,0,GO:0007420,brain development,M1000010,2,0
1,0,0,0,0,0,1,-4.6,0,0,0,0,0,-4.7,R-HSA-2428924,IGF1R signaling cascade,M1000001,2,0
1,0,0,0,0,0,1,-2.4,0,0,0,0,0,-3.7,R-HSA-9006931,Signaling by Nuclear Receptors,M1000001,2,0
1,0,0,0,0,1,0,-3,0,0,0,0,-3.1,0,GO:0000165,MAPK cascade,M1000010,2,0
1,0,0,0,0,0,1,-3.4,0,0,0,0,0,-2.4,GO:0003002,regionalization,M1000001,2,0
1,0,0,0,0,0,1,-2.5,0,0,0,0,0,-3.8,GO:0007548,sex differentiation,M1000001,2,0
1,0,0,0,0,0,1,-5.2,0,0,0,0,0,-5.3,WP710,DNA damage response (only ATM dependent),M1000001,2,0
0,0,0,0,0,1,1,0,0,0,0,0,-2.1,-3.1,GO:0048608,reproductive structure development,M0000011,2,0
1,0,0,0,0,0,1,-3.3,0,0,0,0,0,-4.9,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,M1000001,2,0
1,0,0,0,0,0,1,-5.3,0,0,0,0,0,-3.8,WP399,Wnt signaling pathway and pluripotency,M1000001,2,0
1,0,0,0,0,0,1,-3.8,0,0,0,0,0,-5.5,hsa04916,Melanogenesis,M1000001,2,0
1,0,0,0,0,0,1,-4.1,0,0,0,0,0,-2.3,GO:0002520,immune system development,M1000001,2,0
1,0,0,0,0,0,1,-5,0,0,0,0,0,-3.5,WP236,Adipogenesis,M1000001,2,0
0,0,0,0,0,1,1,0,0,0,0,0,-2,-2,GO:0048568,embryonic organ development,M0000011,2,0
1,0,0,0,0,0,1,-3.6,0,0,0,0,0,-2.7,GO:0007507,heart development,M1000001,2,0
1,0,0,0,1,0,0,-6.3,0,0,0,-2.6,0,0,GO:0001822,kidney development,M1000100,2,0
1,0,0,0,0,0,1,-2.8,0,0,0,0,0,-2.9,GO:0061448,connective tissue development,M1000001,2,0
1,0,0,0,0,0,1,-5,0,0,0,0,0,-5,R-HSA-5654743,Signaling by FGFR4,M1000001,2,0
1,0,0,0,0,0,1,-4,0,0,0,0,0,-4.1,hsa04012,ErbB signaling pathway,M1000001,2,0
0,0,1,0,0,0,1,0,0,-3,0,0,0,-6.6,GO:0043408,regulation of MAPK cascade,M0010001,2,0
1,0,0,0,0,0,1,-2.8,0,0,0,0,0,-4.2,R-HSA-8939211,ESR-mediated signaling,M1000001,2,0
1,0,0,0,0,0,1,-3.6,0,0,0,0,0,-7,WP4659,Gastrin signaling pathway,M1000001,2,0
1,0,0,0,0,0,1,-5,0,0,0,0,0,-5.1,R-HSA-5654741,Signaling by FGFR3,M1000001,2,0
1,0,0,0,0,0,1,-2.1,0,0,0,0,0,-3.3,hsa05010,Alzheimer disease,M1000001,2,0
1,0,0,0,0,0,1,-4.7,0,0,0,0,0,-4.8,WP4666,Hepatitis B infection,M1000001,2,0
0,0,0,0,0,1,1,0,0,0,0,0,-2.1,-3.1,GO:0061458,reproductive system development,M0000011,2,0
1,0,0,0,0,1,0,-4.7,0,0,0,0,-3.3,0,hsa04921,Oxytocin signaling pathway,M1000010,2,0
1,0,0,0,0,0,1,-4.5,0,0,0,0,0,-11,hsa05225,Hepatocellular carcinoma,M1000001,2,0
1,0,0,0,0,0,1,-4.1,0,0,0,0,0,-6,R-HSA-74752,Signaling by Insulin receptor,M1000001,2,0
1,0,1,0,0,0,0,-3.9,0,-3.6,0,0,0,0,R-HSA-500792,GPCR ligand binding,M1010000,2,0
1,0,0,0,0,0,1,-5.2,0,0,0,0,0,-9.5,WP5087,Malignant pleural mesothelioma,M1000001,2,0
1,0,0,0,0,0,1,-2.3,0,0,0,0,0,-3.5,WP2059,Alzheimer's disease and miRNA effects,M1000001,2,0
1,0,0,1,0,0,0,-4.8,0,0,-3.7,0,0,0,GO:0060562,epithelial tube morphogenesis,M1001000,2,0
1,0,0,0,0,0,1,-3.5,0,0,0,0,0,-2.6,GO:0048598,embryonic morphogenesis,M1000001,2,0
1,0,0,0,0,0,1,-2.9,0,0,0,0,0,-4.4,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M1000001,2,0
1,0,0,0,0,0,1,-3.8,0,0,0,0,0,-2.7,GO:0043588,skin development,M1000001,2,0
1,0,0,0,0,0,1,-2.2,0,0,0,0,0,-2.3,GO:0002521,leukocyte differentiation,M1000001,2,0
0,0,0,0,0,1,1,0,0,0,0,0,-2.9,-2.9,GO:0060348,bone development,M0000011,2,0
1,0,0,0,0,0,1,-2.8,0,0,0,0,0,-2.8,GO:0048705,skeletal system morphogenesis,M1000001,2,0
1,0,0,0,0,0,1,-2.3,0,0,0,0,0,-4.4,GO:0001775,cell activation,M1000001,2,0
1,0,0,0,1,0,0,-6.2,0,0,0,-2.6,0,0,GO:0072001,renal system development,M1000100,2,0
1,0,0,0,0,1,0,-2,0,0,0,0,-3.2,0,GO:0008015,blood circulation,M1000010,2,0
1,0,0,0,0,0,1,-2.6,0,0,0,0,0,-5.2,R-HSA-1257604,PIP3 activates AKT signaling,M1000001,2,0
1,0,0,0,0,0,1,-2.8,0,0,0,0,0,-2.9,GO:0009952,anterior/posterior pattern specification,M1000001,2,0
1,0,0,0,0,0,1,-4.8,0,0,0,0,0,-4.9,M70,PID PS1 PATHWAY,M1000001,2,0
1,0,0,0,0,0,1,-4.1,0,0,0,0,0,-4.2,hsa05166,Human T-cell leukemia virus 1 infection,M1000001,2,0
1,0,0,0,0,0,1,-10,0,0,0,0,0,-6.9,WP3931,Embryonic stem cell pluripotency pathways,M1000001,2,0
1,0,0,0,0,0,1,-2.3,0,0,0,0,0,-2.4,GO:0090287,regulation of cellular response to growth factor stimulus,M1000001,2,0
1,0,0,0,0,1,0,-3,0,0,0,0,-3.1,0,GO:0099177,regulation of trans-synaptic signaling,M1000010,2,0
1,0,0,0,0,1,0,-3.5,0,0,0,0,-3.6,0,GO:0050890,cognition,M1000010,2,0
1,0,0,0,0,1,0,-3.8,0,0,0,0,-2.7,0,GO:0042692,muscle cell differentiation,M1000010,2,0
1,0,0,0,0,1,0,-3.8,0,0,0,0,-3.9,0,GO:0060840,artery development,M1000010,2,0
1,0,0,0,0,0,1,-2.9,0,0,0,0,0,-3,hsa05203,Viral carcinogenesis,M1000001,2,0
1,0,0,0,0,0,1,-4.2,0,0,0,0,0,-6.1,hsa05218,Melanoma,M1000001,2,0
1,0,0,0,0,0,1,-3.2,0,0,0,0,0,-3.3,GO:0051216,cartilage development,M1000001,2,0
1,0,0,0,0,0,1,-4,0,0,0,0,0,-2,GO:0051960,regulation of nervous system development,M1000001,2,0
1,0,0,0,0,0,1,-3.1,0,0,0,0,0,-3.2,hsa04310,Wnt signaling pathway,M1000001,2,0
1,0,0,0,0,0,1,-3.5,0,0,0,0,0,-4.9,R-HSA-9006925,Intracellular signaling by second messengers,M1000001,2,0
1,0,0,0,0,0,1,-2.5,0,0,0,0,0,-3.8,R-HSA-5684996,MAPK1/MAPK3 signaling,M1000001,2,0
1,0,0,0,0,0,1,-3.2,0,0,0,0,0,-4.7,GO:0046661,male sex differentiation,M1000001,2,0
1,0,0,0,0,0,1,-6.1,0,0,0,0,0,-9.6,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M1000001,2,0
1,0,0,0,0,0,1,-4,0,0,0,0,0,-4.1,R-HSA-190236,Signaling by FGFR,M1000001,2,0
1,0,0,0,0,1,0,-3.5,0,0,0,0,-2.4,0,GO:1901214,regulation of neuron death,M1000010,2,0
1,0,0,0,0,0,1,-4.2,0,0,0,0,0,-2.4,GO:0048534,hematopoietic or lymphoid organ development,M1000001,2,0
1,0,0,0,0,0,1,-4.6,0,0,0,0,0,-6.6,R-HSA-74751,Insulin receptor signalling cascade,M1000001,2,0
1,0,0,0,0,0,1,-6.8,0,0,0,0,0,-6.9,WP4787,Osteoblast differentiation and related diseases,M1000001,2,0
1,0,0,0,0,0,1,-2.2,0,0,0,0,0,-2.3,GO:0050767,regulation of neurogenesis,M1000001,2,0
1,0,0,0,0,0,1,-4.7,0,0,0,0,0,-4.8,R-HSA-5654736,Signaling by FGFR1,M1000001,2,0
1,0,0,0,0,1,0,-5.3,0,0,0,0,-2.7,0,GO:0045165,cell fate commitment,M1000010,2,0
1,0,0,0,0,0,1,-3.6,0,0,0,0,0,-3.7,R-HSA-187037,Signaling by NTRK1 (TRKA),M1000001,2,0
1,0,0,0,0,0,1,-2.2,0,0,0,0,0,-2.3,GO:1901342,regulation of vasculature development,M1000001,2,0
1,0,0,0,0,0,1,-2.3,0,0,0,0,0,-2.4,R-HSA-195721,Signaling by WNT,M1000001,2,0
1,0,0,0,1,0,0,-3,0,0,0,-3.3,0,0,GO:0010564,regulation of cell cycle process,M1000100,2,0
1,0,0,0,0,0,1,-3.9,0,0,0,0,0,-4,WP673,ErbB signaling pathway,M1000001,2,0
1,0,0,0,0,0,1,-3.2,0,0,0,0,0,-2.3,GO:0048871,multicellular organismal homeostasis,M1000001,2,0
1,0,0,0,0,0,1,-2.5,0,0,0,0,0,-3.8,R-HSA-5673001,RAF/MAP kinase cascade,M1000001,2,0
1,0,0,0,0,0,1,-2.5,0,0,0,0,0,-2.6,GO:0051962,positive regulation of nervous system development,M1000001,2,0
1,0,0,0,0,1,0,-3,0,0,0,0,-3.1,0,GO:0050804,modulation of chemical synaptic transmission,M1000010,2,0
1,0,0,0,0,0,1,-3,0,0,0,0,0,-3.1,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M1000001,2,0
1,0,0,0,0,0,1,-4.6,0,0,0,0,0,-4.7,hsa05161,Hepatitis B,M1000001,2,0
1,0,0,0,0,0,1,-3.4,0,0,0,0,0,-3.5,R-HSA-166520,Signaling by NTRKs,M1000001,2,0
1,0,0,0,0,0,1,-4.6,0,0,0,0,0,-4.6,M276,PID FGF PATHWAY,M1000001,2,0
1,0,0,0,0,1,0,-5.6,0,0,0,0,-3.3,0,GO:0030900,forebrain development,M1000010,2,0
1,0,0,0,0,0,1,-6.3,0,0,0,0,0,-12,hsa05226,Gastric cancer,M1000001,2,0
1,0,0,0,0,0,1,-2.4,0,0,0,0,0,-3.5,GO:0010942,positive regulation of cell death,M1000001,2,0
1,0,0,0,0,0,1,-3.2,0,0,0,0,0,-3.3,hsa04150,mTOR signaling pathway,M1000001,2,0
0,0,1,0,0,0,1,0,0,-2.4,0,0,0,-6.4,GO:0043410,positive regulation of MAPK cascade,M0010001,2,0
1,0,0,0,0,0,1,-2.9,0,0,0,0,0,-2,GO:0007389,pattern specification process,M1000001,2,0
1,0,0,0,0,0,1,-2.8,0,0,0,0,0,-2.9,GO:0008406,gonad development,M1000001,2,0
0,0,1,0,0,1,0,0,0,-2.8,0,0,-2.3,0,hsa04080,Neuroactive ligand-receptor interaction,M0010010,2,0
1,0,0,0,0,0,1,-3.4,0,0,0,0,0,-3.5,GO:0001525,angiogenesis,M1000001,2,0
1,0,0,0,0,0,1,-3.4,0,0,0,0,0,-3.5,R-HSA-5683057,MAPK family signaling cascades,M1000001,2,0
1,0,0,0,0,0,1,-2.6,0,0,0,0,0,-3.9,WP5124,Alzheimer's disease,M1000001,2,0
1,0,0,0,0,1,0,-3.8,0,0,0,0,-3.9,0,GO:0007611,learning or memory,M1000010,2,0
1,0,0,0,0,0,1,-2.8,0,0,0,0,0,-2.8,GO:0045137,development of primary sexual characteristics,M1000001,2,0
1,0,0,0,0,0,1,-4.2,0,0,0,0,0,-4.3,R-HSA-5654738,Signaling by FGFR2,M1000001,2,0
1,0,0,0,1,0,0,-5.9,0,0,0,-2.4,0,0,GO:0001655,urogenital system development,M1000100,2,0
1,0,0,0,0,0,1,-2.1,0,0,0,0,0,-4.1,GO:0009725,response to hormone,M1000001,2,0
1,0,0,0,0,0,1,-4.8,0,0,0,0,0,-4.9,hsa04550,Signaling pathways regulating pluripotency of stem cells,M1000001,2,0
1,0,0,0,0,0,1,-3.4,0,0,0,0,0,-8.3,GO:0007167,enzyme-linked receptor protein signaling pathway,M1000001,2,0
1,0,0,0,0,0,1,-3.1,0,0,0,0,0,-3.2,GO:0010001,glial cell differentiation,M1000001,2,0
1,0,0,0,0,0,1,-5.1,0,0,0,0,0,-3.6,GO:0035270,endocrine system development,M1000001,2,0
1,0,0,0,0,0,1,-4.6,0,0,0,0,0,-4.7,R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),M1000001,2,0
1,0,0,0,0,0,1,-2.4,0,0,0,0,0,-2.5,GO:1903131,mononuclear cell differentiation,M1000001,2,0
1,0,0,0,0,0,1,-2.8,0,0,0,0,0,-5.7,hsa04015,Rap1 signaling pathway,M1000001,2,0
1,0,0,0,0,0,1,-4.1,0,0,0,0,0,-4.3,hsa05207,Chemical carcinogenesis - receptor activation,M1000001,2,0
0,0,0,0,1,0,1,0,0,0,0,-4.1,0,-2.7,GO:0033044,regulation of chromosome organization,M0000101,2,0
1,0,0,0,0,1,0,-2.3,0,0,0,0,-2.4,0,R-HSA-418594,G alpha (i) signalling events,M1000010,2,0
1,0,0,0,0,0,0,-7.8,0,0,0,0,0,0,GO:0072080,nephron tubule development,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.9,GO:0032868,response to insulin,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.8,0,0,GO:0007052,mitotic spindle organization,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-8.2,WP4685,Melanoma,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.3,GO:0045834,positive regulation of lipid metabolic process,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.5,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M0000001,1,0
1,0,0,0,0,0,0,-4.9,0,0,0,0,0,0,GO:0007517,muscle organ development,M1000000,1,0
1,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,GO:0061138,morphogenesis of a branching epithelium,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.9,WP23,B cell receptor signaling pathway,M0000001,1,0
1,0,0,0,0,0,0,-4.2,0,0,0,0,0,0,GO:0021536,diencephalon development,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.2,0,0,GO:0007017,microtubule-based process,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,hsa05202,Transcriptional misregulation in cancer,M0000001,1,0
1,0,0,0,0,0,0,-5.1,0,0,0,0,0,0,GO:0001889,liver development,M1000000,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,GO:0001823,mesonephros development,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.7,R-HSA-9006936,Signaling by TGFB family members,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.1,0,0,R-HSA-453274,Mitotic G2-G2/M phases,M0000100,1,0
0,0,0,0,1,0,0,0,0,0,0,-4,0,0,GO:0051225,spindle assembly,M0000100,1,0
1,0,0,0,0,0,0,-5,0,0,0,0,0,0,GO:0061008,hepaticobiliary system development,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.3,0,0,GO:0051985,negative regulation of chromosome segregation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.5,WP304,Kit receptor signaling pathway,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-4.6,0,GO:0030199,collagen fibril organization,M0000010,1,0
1,0,0,0,0,0,0,-6.6,0,0,0,0,0,0,GO:0072073,kidney epithelium development,M1000000,1,0
1,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,GO:0150063,visual system development,M1000000,1,0
1,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,GO:0044089,positive regulation of cellular component biogenesis,M1000000,1,0
1,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,GO:0050678,regulation of epithelial cell proliferation,M1000000,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,R-HSA-157118,Signaling by NOTCH,M1000000,1,0
1,0,0,0,0,0,0,-5.3,0,0,0,0,0,0,R-HSA-5654687,Downstream signaling of activated FGFR1,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,hsa04062,Chemokine signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4,hsa05222,Small cell lung cancer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.8,GO:0060284,regulation of cell development,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-12,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M0000001,1,0
1,0,0,0,0,0,0,-4.2,0,0,0,0,0,0,R-HSA-1980143,Signaling by NOTCH1,M1000000,1,0
1,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,GO:0030097,hemopoiesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.9,GO:0032870,cellular response to hormone stimulus,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-4.3,0,0,GO:2001251,negative regulation of chromosome organization,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.8,R-HSA-9634638,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.9,GO:0071902,positive regulation of protein serine/threonine kinase activity,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.5,GO:1902105,regulation of leukocyte differentiation,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.1,0,0,R-HSA-69275,G2/M Transition,M0000100,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,GO:1901990,regulation of mitotic cell cycle phase transition,M0000100,1,0
1,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,WP289,Myometrial relaxation and contraction pathways,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-4,0,0,GO:1902099,regulation of metaphase/anaphase transition of cell cycle,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,R-HSA-9711123,Cellular response to chemical stress,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.1,R-HSA-112316,Neuronal System,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.7,0,0,GO:0140694,non-membrane-bounded organelle assembly,M0000100,1,0
1,0,0,0,0,0,0,-5.5,0,0,0,0,0,0,WP3845,Canonical and non-canonical Notch signaling,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.2,GO:0051098,regulation of binding,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5,R-HSA-2262752,Cellular responses to stress,M0000001,1,0
1,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,GO:0060675,ureteric bud morphogenesis,M1000000,1,0
1,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,GO:1901890,positive regulation of cell junction assembly,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.4,GO:0035065,regulation of histone acetylation,M0000001,1,0
1,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,GO:0007423,sensory organ development,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4,WP2840,Hair follicle development: cytodifferentiation - part 3 of 3,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.4,GO:0042060,wound healing,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.2,WP4331,Neovascularisation processes,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.5,GO:0008286,insulin receptor signaling pathway,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-3.6,0,GO:0032355,response to estradiol,M0000010,1,0
1,0,0,0,0,0,0,-5.9,0,0,0,0,0,0,R-HSA-5654719,SHC-mediated cascade:FGFR4,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.7,0,0,GO:0007093,mitotic cell cycle checkpoint signaling,M0000100,1,0
0,0,1,0,0,0,0,0,0,-2.1,0,0,0,0,GO:0019725,cellular homeostasis,M0010000,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.6,0,0,GO:0071173,spindle assembly checkpoint signaling,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.2,GO:0007568,aging,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.5,hsa04371,Apelin signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5,WP2036,TNF-related weak inducer of apoptosis (TWEAK) signaling pathway,M0000001,1,0
1,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,GO:0046903,secretion,M1000000,1,0
1,0,0,0,0,0,0,-6.5,0,0,0,0,0,0,GO:0060538,skeletal muscle organ development,M1000000,1,0
1,0,0,0,0,0,0,-3.9,0,0,0,0,0,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M1000000,1,0
1,0,0,0,0,0,0,-5.7,0,0,0,0,0,0,R-HSA-5654699,SHC-mediated cascade:FGFR2,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.8,R-HSA-201681,TCF dependent signaling in response to WNT,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-4.9,0,0,GO:0090307,mitotic spindle assembly,M0000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,GO:0098655,cation transmembrane transport,M0000010,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.7,M7955,SIG INSULIN RECEPTOR PATHWAY IN CARDIAC MYOCYTES,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.9,0,0,GO:1901988,negative regulation of cell cycle phase transition,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.4,hsa04261,Adrenergic signaling in cardiomyocytes,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.4,R-HSA-5653656,Vesicle-mediated transport,M0000001,1,0
1,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,GO:1901888,regulation of cell junction assembly,M1000000,1,0
1,0,0,0,0,0,0,-4.8,0,0,0,0,0,0,GO:1901861,regulation of muscle tissue development,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.3,hsa04934,Cushing syndrome,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.8,GO:0010035,response to inorganic substance,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.1,WP4806,EGFR tyrosine kinase inhibitor resistance,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,GO:0070482,response to oxygen levels,M0000010,1,0
1,0,0,0,0,0,0,-4.5,0,0,0,0,0,0,GO:0001763,morphogenesis of a branching structure,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.8,GO:0043065,positive regulation of apoptotic process,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.3,0,0,GO:1902850,microtubule cytoskeleton organization involved in mitosis,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.3,hsa01524,Platinum drug resistance,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.5,GO:0010720,positive regulation of cell development,M0000001,1,0
1,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,GO:0072078,nephron tubule morphogenesis,M1000000,1,0
1,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,hsa04810,Regulation of actin cytoskeleton,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.6,GO:0071417,cellular response to organonitrogen compound,M0000001,1,0
1,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,R-HSA-5619507,Activation of HOX genes during differentiation,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-4,0,0,R-HSA-141444,Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.7,GO:0051052,regulation of DNA metabolic process,M0000001,1,0
1,0,0,0,0,0,0,-4.8,0,0,0,0,0,0,GO:0060537,muscle tissue development,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.6,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6,hsa05212,Pancreatic cancer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.4,GO:0045859,regulation of protein kinase activity,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,GO:0070302,regulation of stress-activated protein kinase signaling cascade,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.9,R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.9,GO:0071773,cellular response to BMP stimulus,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-5.1,0,GO:0046683,response to organophosphorus,M0000010,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.6,0,0,GO:0071174,mitotic spindle checkpoint signaling,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6.1,GO:0034654,nucleobase-containing compound biosynthetic process,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.2,hsa05163,Human cytomegalovirus infection,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,M0000001,1,0
1,0,0,0,0,0,0,-3.9,0,0,0,0,0,0,hsa04912,GnRH signaling pathway,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.8,GO:0071375,cellular response to peptide hormone stimulus,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.2,0,0,GO:0007059,chromosome segregation,M0000100,1,0
1,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,GO:2000144,"positive regulation of DNA-templated transcription, initiation",M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.2,hsa04022,cGMP-PKG signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.8,R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6.6,WP5144,NRP1-triggered signaling pathways in pancreatic cancer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.3,WP4255,Non-small cell lung cancer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.1,GO:0045860,positive regulation of protein kinase activity,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.7,hsa05132,Salmonella infection,M0000001,1,0
1,0,0,0,0,0,0,-4.9,0,0,0,0,0,0,GO:0001658,branching involved in ureteric bud morphogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,GO:0051090,regulation of DNA-binding transcription factor activity,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.1,GO:1903706,regulation of hemopoiesis,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4,WP138,Androgen receptor signaling pathway,M0000001,1,0
1,0,0,0,0,0,0,-7.7,0,0,0,0,0,0,GO:0061326,renal tubule development,M1000000,1,0
1,0,0,0,0,0,0,-5,0,0,0,0,0,0,WP127,IL-5 signaling pathway,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6,WP4674,Head and neck squamous cell carcinoma,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-4.4,0,GO:0048844,artery morphogenesis,M0000010,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-4.4,0,M3008,NABA ECM GLYCOPROTEINS,M0000010,1,0
1,0,0,0,0,0,0,-4.7,0,0,0,0,0,0,R-HSA-112399,IRS-mediated signalling,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.2,GO:1901652,response to peptide,M0000001,1,0
1,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,GO:0032940,secretion by cell,M1000000,1,0
1,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,GO:0071559,response to transforming growth factor beta,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.7,M286,PID TGFBR PATHWAY,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.7,GO:0006366,transcription by RNA polymerase II,M0000001,1,0
1,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,GO:0072088,nephron epithelium morphogenesis,M1000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-3.4,0,GO:0035296,regulation of tube diameter,M0000010,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.4,0,0,GO:0000075,cell cycle checkpoint signaling,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.6,R-HSA-112315,Transmission across Chemical Synapses,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.1,0,0,R-HSA-2467813,Separation of Sister Chromatids,M0000100,1,0
1,0,0,0,0,0,0,-3.9,0,0,0,0,0,0,GO:0003007,heart morphogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.9,M8626,SIG BCR SIGNALING PATHWAY,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.2,hsa05216,Thyroid cancer,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.3,0,0,GO:0070925,organelle assembly,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.3,hsa05160,Hepatitis C,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5,0,0,GO:0051783,regulation of nuclear division,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2,GO:0009611,response to wounding,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-4.9,0,0,GO:0007051,spindle organization,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.1,R-HSA-109581,Apoptosis,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.9,GO:0050769,positive regulation of neurogenesis,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.1,hsa04068,FoxO signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.5,GO:0008584,male gonad development,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.5,GO:1901653,cellular response to peptide,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.6,GO:0043434,response to peptide hormone,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.7,0,0,R-HSA-2500257,Resolution of Sister Chromatid Cohesion,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.8,hsa04928,"Parathyroid hormone synthesis, secretion and action",M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.8,0,GO:0009636,response to toxic substance,M0000010,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.2,GO:0071345,cellular response to cytokine stimulus,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.7,0,GO:1903522,regulation of blood circulation,M0000010,1,0
1,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-4.8,0,0,GO:0140014,mitotic nuclear division,M0000100,1,0
1,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,WP428,Wnt signaling,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.7,R-HSA-422475,Axon guidance,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4,GO:0043549,regulation of kinase activity,M0000001,1,0
1,0,0,0,0,0,0,-5.1,0,0,0,0,0,0,GO:0045746,negative regulation of Notch signaling pathway,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.3,R-HSA-199418,Negative regulation of the PI3K/AKT network,M0000001,1,0
1,0,0,0,0,0,0,-3,0,0,0,0,0,0,GO:2000241,regulation of reproductive process,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,R-HSA-194315,Signaling by Rho GTPases,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5,hsa04915,Estrogen signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.5,WP4816,TGF-beta receptor signaling in skeletal dysplasias,M0000001,1,0
1,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,GO:0001654,eye development,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.6,0,0,GO:0007094,mitotic spindle assembly checkpoint signaling,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.1,GO:0046649,lymphocyte activation,M0000001,1,0
1,0,0,0,0,0,0,-4.1,0,0,0,0,0,0,GO:0002065,columnar/cuboidal epithelial cell differentiation,M1000000,1,0
1,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,WP51,Regulation of actin cytoskeleton,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.9,0,0,GO:0010948,negative regulation of cell cycle process,M0000100,1,0
1,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,GO:0009410,response to xenobiotic stimulus,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.7,GO:0051054,positive regulation of DNA metabolic process,M0000001,1,0
1,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,GO:0061333,renal tubule morphogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.9,WP4658,Small cell lung cancer,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-4.4,0,0,R-HSA-68877,Mitotic Prometaphase,M0000100,1,0
1,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,GO:0072171,mesonephric tubule morphogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.4,WP5083,Neuroinflammation and glutamatergic signaling,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.6,0,0,GO:0051983,regulation of chromosome segregation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.3,GO:0007492,endoderm development,M0000001,1,0
1,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,M186,PID PDGFRB PATHWAY,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.9,GO:0071772,response to BMP,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-8.4,GO:0097659,nucleic acid-templated transcription,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.5,GO:0046546,development of primary male sexual characteristics,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-9.2,0,0,GO:1903047,mitotic cell cycle process,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.4,WP2374,Oncostatin M signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.5,hsa04210,Apoptosis,M0000001,1,0
1,0,0,0,0,0,0,-5.8,0,0,0,0,0,0,R-HSA-5654712,FRS-mediated FGFR4 signaling,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.5,hsa04910,Insulin signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.6,hsa04380,Osteoclast differentiation,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.2,GO:2000756,regulation of peptidyl-lysine acetylation,M0000001,1,0
0,0,1,0,0,0,0,0,0,-4.1,0,0,0,0,GO:0001649,osteoblast differentiation,M0010000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.4,WP3303,RAC1/PAK1/p38/MMP2 pathway,M0000001,1,0
1,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,GO:0043523,regulation of neuron apoptotic process,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-8.6,0,0,GO:0000278,mitotic cell cycle,M0000100,1,0
1,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.5,0,0,GO:0031577,spindle checkpoint signaling,M0000100,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.4,0,0,GO:1902100,negative regulation of metaphase/anaphase transition of cell cycle,M0000100,1,0
1,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,WP437,EGF/EGFR signaling pathway,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.1,GO:0022412,cellular process involved in reproduction in multicellular organism,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.8,0,0,R-HSA-69278,"Cell Cycle, Mitotic",M0000100,1,0
1,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,GO:0043010,camera-type eye development,M1000000,1,0
1,0,0,0,0,0,0,-5.6,0,0,0,0,0,0,R-HSA-5654708,Downstream signaling of activated FGFR3,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.6,0,0,GO:0010639,negative regulation of organelle organization,M0000100,1,0
1,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,GO:0043524,negative regulation of neuron apoptotic process,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.3,WP481,Insulin signaling,M0000001,1,0
1,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,hsa04390,Hippo signaling pathway,M1000000,1,0
1,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,GO:0021537,telencephalon development,M1000000,1,0
1,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,GO:0008593,regulation of Notch signaling pathway,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.4,M295,SIG PIP3 SIGNALING IN CARDIAC MYOCTES,M0000001,1,0
1,0,0,0,0,0,0,-5.7,0,0,0,0,0,0,R-HSA-5654693,FRS-mediated FGFR1 signaling,M1000000,1,0
1,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,hsa05417,Lipid and atherosclerosis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.6,R-HSA-8878166,Transcriptional regulation by RUNX2,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6,R-HSA-9009391,Extra-nuclear estrogen signaling,M0000001,1,0
1,0,0,0,0,0,0,-6.7,0,0,0,0,0,0,GO:0007519,skeletal muscle tissue development,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6.8,hsa04926,Relaxin signaling pathway,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.9,0,0,GO:0033045,regulation of sister chromatid segregation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.2,hsa01521,EGFR tyrosine kinase inhibitor resistance,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.4,R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.7,WP3668,Hypothesized pathways in pathogenesis of cardiovascular disease,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-4.1,0,GO:0006936,muscle contraction,M0000010,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.4,0,0,R-HSA-1640170,Cell Cycle,M0000100,1,0
1,0,0,0,0,0,0,-5.2,0,0,0,0,0,0,WP422,MAPK cascade,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.9,0,0,R-HSA-68882,Mitotic Anaphase,M0000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.7,0,GO:0003018,vascular process in circulatory system,M0000010,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6,WP2034,Leptin signaling pathway,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.5,0,GO:0036293,response to decreased oxygen levels,M0000010,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.5,0,0,R-HSA-5663220,RHO GTPases Activate Formins,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.2,GO:0006091,generation of precursor metabolites and energy,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-3.4,0,GO:0097746,blood vessel diameter maintenance,M0000010,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.4,GO:1901699,cellular response to nitrogen compound,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.3,hsa05230,Central carbon metabolism in cancer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.2,GO:0071900,regulation of protein serine/threonine kinase activity,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.4,GO:0032869,cellular response to insulin stimulus,M0000001,1,0
1,0,0,0,0,0,0,-4.9,0,0,0,0,0,0,GO:0048754,branching morphogenesis of an epithelial tube,M1000000,1,0
1,0,0,0,0,0,0,-4.1,0,0,0,0,0,0,GO:2000142,"regulation of DNA-templated transcription, initiation",M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,GO:0009612,response to mechanical stimulus,M0000001,1,0
1,0,0,0,0,0,0,-3,0,0,0,0,0,0,GO:0051302,regulation of cell division,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.3,GO:0019216,regulation of lipid metabolic process,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.7,0,0,GO:0000070,mitotic sister chromatid segregation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.9,M48,PID MET PATHWAY,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.4,0,0,GO:0007088,regulation of mitotic nuclear division,M0000100,1,0
1,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,GO:1901215,negative regulation of neuron death,M1000000,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,GO:0072164,mesonephric tubule development,M1000000,1,0
1,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,GO:0044057,regulation of system process,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.3,GO:0007369,gastrulation,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.6,WP560,TGF-beta receptor signaling,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.8,hsa04218,Cellular senescence,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.6,M1718,SIG IL4RECEPTOR IN B LYPHOCYTES,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,WP2882,Nuclear receptors meta-pathway,M0000010,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.5,0,0,GO:0045841,negative regulation of mitotic metaphase/anaphase transition,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.2,GO:0007276,gamete generation,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.9,0,0,GO:0045930,negative regulation of mitotic cell cycle,M0000100,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.6,0,0,R-HSA-195258,RHO GTPase Effectors,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.5,GO:0007281,germ cell development,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.7,M231,PID KIT PATHWAY,M0000001,1,0
1,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,GO:2000027,regulation of animal organ morphogenesis,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.2,0,0,R-HSA-68886,M Phase,M0000100,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.2,0,0,GO:0045839,negative regulation of mitotic nuclear division,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.1,M115,PID REG GR PATHWAY,M0000001,1,0
1,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,GO:0110149,regulation of biomineralization,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.5,R-HSA-375165,NCAM signaling for neurite out-growth,M0000001,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,GO:0030500,regulation of bone mineralization,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-9.6,hsa05210,Colorectal cancer,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.2,0,0,GO:1901991,negative regulation of mitotic cell cycle phase transition,M0000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.8,0,GO:0003013,circulatory system process,M0000010,1,0
1,0,0,0,0,0,0,-5.6,0,0,0,0,0,0,R-HSA-5654700,FRS-mediated FGFR2 signaling,M1000000,1,0
1,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,WP2857,Mesodermal commitment pathway,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.4,0,0,GO:0033048,negative regulation of mitotic sister chromatid segregation,M0000100,1,0
1,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,GO:0072028,nephron morphogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.8,GO:0097305,response to alcohol,M0000001,1,0
1,0,0,0,0,0,0,-5.8,0,0,0,0,0,0,R-HSA-5654688,SHC-mediated cascade:FGFR1,M1000000,1,0
1,0,0,0,0,0,0,-4.7,0,0,0,0,0,0,WP2848,Pluripotent stem cell differentiation pathway,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-4,0,0,GO:0010965,regulation of mitotic sister chromatid separation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-8.3,GO:0032774,RNA biosynthetic process,M0000001,1,0
1,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4,WP2355,Corticotropin-releasing hormone signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.1,hsa05034,Alcoholism,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.3,hsa04917,Prolactin signaling pathway,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.8,0,0,R-HSA-9648025,EML4 and NUDC in mitotic spindle formation,M0000100,1,0
1,0,0,0,0,0,0,-5.1,0,0,0,0,0,0,R-HSA-5655302,Signaling by FGFR1 in disease,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,GO:0051129,negative regulation of cellular component organization,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.2,hsa04935,"Growth hormone synthesis, secretion and action",M0000001,1,0
1,0,0,0,0,0,0,-6.1,0,0,0,0,0,0,R-HSA-5654704,SHC-mediated cascade:FGFR3,M1000000,1,0
1,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,R-HSA-2428928,IRS-related events triggered by IGF1R,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6.5,hsa05213,Endometrial cancer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,WP3888,VEGFA-VEGFR2 signaling pathway,M0000001,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,GO:0072163,mesonephric epithelium development,M1000000,1,0
1,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,GO:0090068,positive regulation of cell cycle process,M1000000,1,0
1,0,0,0,0,0,0,-7.2,0,0,0,0,0,0,GO:0072009,nephron epithelium development,M1000000,1,0
1,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,GO:0048167,regulation of synaptic plasticity,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.6,WP4754,IL-18 signaling pathway,M0000001,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,GO:0071774,response to fibroblast growth factor,M1000000,1,0
1,0,0,0,0,0,0,-5,0,0,0,0,0,0,GO:0021983,pituitary gland development,M1000000,1,0
1,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,R-HSA-1226099,Signaling by FGFR in disease,M1000000,1,0
1,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,GO:0071560,cellular response to transforming growth factor beta stimulus,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.3,GO:0045765,regulation of angiogenesis,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.3,WP706,Sudden infant death syndrome (SIDS) susceptibility pathways,M0000001,1,0
1,0,0,0,0,0,0,-5.6,0,0,0,0,0,0,GO:0031128,developmental induction,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,R-HSA-382551,Transport of small molecules,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.5,GO:0043009,chordate embryonic development,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.6,GO:0051091,positive regulation of DNA-binding transcription factor activity,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.9,0,0,GO:1905818,regulation of chromosome separation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.9,GO:0098609,cell-cell adhesion,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.2,GO:0080135,regulation of cellular response to stress,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-4.1,0,0,GO:0030071,regulation of mitotic metaphase/anaphase transition,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.4,R-HSA-9614085,FOXO-mediated transcription,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.6,hsa05215,Prostate cancer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.5,M254,PID MYC REPRESS PATHWAY,M0000001,1,0
1,0,0,0,0,0,0,-4.1,0,0,0,0,0,0,GO:0003151,outflow tract morphogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.6,hsa04919,Thyroid hormone signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-8.4,GO:0006351,"transcription, DNA-templated",M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5,0,0,GO:0051784,negative regulation of nuclear division,M0000100,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,GO:2000243,positive regulation of reproductive process,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.7,WP69,T-cell receptor signaling pathway,M0000001,1,0
1,0,0,0,0,0,0,-5.5,0,0,0,0,0,0,R-HSA-5654716,Downstream signaling of activated FGFR4,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.3,hsa05223,Non-small cell lung cancer,M0000001,1,0
1,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-6.5,0,0,GO:0051301,cell division,M0000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-5,0,GO:0014074,response to purine-containing compound,M0000010,1,0
1,0,0,0,0,0,0,-5.1,0,0,0,0,0,0,GO:0030278,regulation of ossification,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.3,0,0,GO:1905819,negative regulation of chromosome separation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.5,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M0000001,1,0
1,0,0,0,0,0,0,-5.8,0,0,0,0,0,0,R-HSA-5655332,Signaling by FGFR3 in disease,M1000000,1,0
1,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,GO:0045787,positive regulation of cell cycle,M1000000,1,0
1,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,GO:0016055,Wnt signaling pathway,M1000000,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,GO:0060993,kidney morphogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.2,GO:0001701,in utero embryonic development,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5,R-HSA-8953897,Cellular responses to stimuli,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.9,0,0,R-HSA-2555396,Mitotic Metaphase and Anaphase,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.3,hsa04520,Adherens junction,M0000001,1,0
1,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,hsa04625,C-type lectin receptor signaling pathway,M1000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-3.4,0,GO:0035150,regulation of tube size,M0000010,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.4,0,0,GO:0045786,negative regulation of cell cycle,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6,WP4223,Ras signaling,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.7,hsa04668,TNF signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.9,GO:0097306,cellular response to alcohol,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5,0,0,GO:0000280,nuclear division,M0000100,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.8,0,0,GO:0051321,meiotic cell cycle,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6,hsa05214,Glioma,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-7.9,hsa05220,Chronic myeloid leukemia,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-4,0,0,R-HSA-141424,Amplification of signal from the kinetochores,M0000100,1,0
1,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,GO:0010817,regulation of hormone levels,M1000000,1,0
1,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,GO:0198738,cell-cell signaling by wnt,M1000000,1,0
1,0,0,0,0,0,0,-4,0,0,0,0,0,0,GO:0001657,ureteric bud development,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.4,0,0,GO:0033046,negative regulation of sister chromatid segregation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.9,hsa04024,cAMP signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.1,M82,PID RET PATHWAY,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6,GO:0031056,regulation of histone modification,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.9,R-HSA-5357801,Programmed Cell Death,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-3.8,0,0,R-HSA-69618,Mitotic Spindle Checkpoint,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6.2,M12771,SA PTEN PATHWAY,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5,0,0,GO:0000819,sister chromatid segregation,M0000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-3.6,0,GO:0007613,memory,M0000010,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.7,GO:0030098,lymphocyte differentiation,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.7,M274,PID LYMPH ANGIOGENESIS PATHWAY,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.4,GO:0009792,embryo development ending in birth or egg hatching,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.8,WP3646,Hepatitis C and hepatocellular carcinoma,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.3,R-HSA-3700989,Transcriptional Regulation by TP53,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.3,GO:0010038,response to metal ion,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4,GO:1901983,regulation of protein acetylation,M0000001,1,0
1,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,GO:0008285,negative regulation of cell population proliferation,M1000000,1,0
1,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,GO:0048880,sensory system development,M1000000,1,0
1,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,GO:1905114,cell surface receptor signaling pathway involved in cell-cell signaling,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.4,hsa05221,Acute myeloid leukemia,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3,GO:0032872,regulation of stress-activated MAPK cascade,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.9,R-HSA-9707616,Heme signaling,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.7,GO:0043068,positive regulation of programmed cell death,M0000001,1,0
1,0,0,0,0,0,0,-6.6,0,0,0,0,0,0,GO:0072006,nephron development,M1000000,1,0
1,0,0,0,0,0,0,-6.2,0,0,0,0,0,0,WP4928,MAPK pathway in congenital thyroid cancer,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.1,0,0,GO:1901987,regulation of cell cycle phase transition,M0000100,1,0
1,0,0,0,0,0,0,-5.4,0,0,0,0,0,0,R-HSA-5654696,Downstream signaling of activated FGFR2,M1000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-5.1,0,GO:0003012,muscle system process,M0000010,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.9,0,0,GO:0007346,regulation of mitotic cell cycle,M0000100,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.9,0,0,GO:0000226,microtubule cytoskeleton organization,M0000100,1,0
1,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,GO:0070167,regulation of biomineral tissue development,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-4.7,0,0,GO:0033047,regulation of mitotic sister chromatid segregation,M0000100,1,0
1,0,0,0,0,0,0,-4.8,0,0,0,0,0,0,GO:0002067,glandular epithelial cell differentiation,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.3,GO:0006468,protein phosphorylation,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-2.6,0,0,R-HSA-69620,Cell Cycle Checkpoints,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.5,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4,GO:0014033,neural crest cell differentiation,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.2,GO:0050878,regulation of body fluid levels,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.5,hsa05152,Tuberculosis,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.3,GO:0019221,cytokine-mediated signaling pathway,M0000001,1,0
1,0,0,0,0,0,0,-5.4,0,0,0,0,0,0,GO:0110110,positive regulation of animal organ morphogenesis,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.1,GO:0030509,BMP signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-6.3,GO:0048863,stem cell differentiation,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.6,hsa04722,Neurotrophin signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.2,WP3929,Chemokine signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4.9,hsa04072,Phospholipase D signaling pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-2.6,R-HSA-9675108,Nervous system development,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.7,hsa04725,Cholinergic synapse,M0000001,1,0
1,0,0,0,0,0,0,-4.7,0,0,0,0,0,0,GO:0050886,endocrine process,M1000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.5,WP3915,Angiopoietin-like protein 8 regulatory pathway,M0000001,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-5.7,WP4263,Pancreatic adenocarcinoma pathway,M0000001,1,0
1,0,0,0,0,0,0,-4.9,0,0,0,0,0,0,R-HSA-5655253,Signaling by FGFR2 in disease,M1000000,1,0
1,0,0,0,0,0,0,-5.9,0,0,0,0,0,0,R-HSA-5654706,FRS-mediated FGFR3 signaling,M1000000,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.7,0,0,GO:0098813,nuclear chromosome segregation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-4,R-HSA-170834,Signaling by TGF-beta Receptor Complex,M0000001,1,0
0,0,0,0,1,0,0,0,0,0,0,-5.4,0,0,GO:2000816,negative regulation of mitotic sister chromatid separation,M0000100,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,-3.8,GO:0031058,positive regulation of histone modification,M0000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-3.9,0,GO:0046620,regulation of organ growth,M0000010,1,0
0,0,0,0,1,0,0,0,0,0,0,-4.9,0,0,GO:0048285,organelle fission,M0000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,GO:0048638,regulation of developmental growth,M0000010,1,0
